Loading...

Canntab Therapeutics Limited

CTABFPNK
HealthcareDrug Manufacturers - Specialty & Generic
$0.00
$0.00(0.00%)

Canntab Therapeutics Limited (CTABF) Stock Overview

Explore Canntab Therapeutics Limited’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for CTABFStats details for CTABF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CTABFAnalyst Recommendations details for CTABF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.

CEO

Mr. Richard C. Goldstein

Headquarters

223 Riviera Drive, Markham, ON

Founded

2017

Frequently Asked Questions